The genetic variant of TM6SF2 promotes the expression of the inflammatory cytokines interleukin (IL)-2 and IL-6 [54] and affects the cell cycle of HCC tumor cells [55]. This evidence concerns the gene TM6SF2 and hepatocellular carcinoma.